# Proof of Novo Nordisk Board Compliance with EU Gender Balance Requirement (2024)

## 📌 EU Requirement
**Directive (EU) 2022/2381 on improving gender balance among directors of listed companies** (adopted 23 November 2022).

- By **June 2026**, listed companies in the EU must ensure that:  
  - At least **40% of non-executive director positions** are held by the underrepresented sex, OR  
  - At least **33% of all director positions** (executive + non-executive) are held by the underrepresented sex.  

🔗 [Directive (EU) 2022/2381 – EUR-Lex](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022L2381)

---

## 📝 Company Statement
**Novo Nordisk Annual Report 2024 (Corporate Governance section)** lists the following **Board of Directors** (12 members):

- Helge Lund (Chair) – Male  
- Henrik Poulsen – Male  
- Elisabeth Dahl Christensen – Female  
- Laurence Debroux – Female  
- Andreas Fibig – Male  
- Sylvie Grégoire – Female  
- Liselotte Hyveled – Female (employee-elected)  
- Mette Bøjer Jensen – Female (employee-elected)  
- Kasim Kutay – Male  
- Christina Law – Female  
- Martin Mackay – Male  
- Thomas Rantzau – Male (employee-elected)  

**Gender distribution (31 Dec 2024):**  
- 6 Women  
- 6 Men  
- **Total: 12 board members**  
- Ratio = **50% women, 50% men**

---

## 🧩 Proof Tree

### Branch 1 – Company Disclosure
- **Source**: Novo Nordisk Annual Report 2024 (legally required governance disclosure).  
- **Claim**: Lists board composition as above.  

### Branch 2 – Independent Market Source
- **Source**: [MarketScreener – Novo Nordisk Company Profile](https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/company/?utm_source=chatgpt.com)  
- **Claim**: Confirms board membership matches Annual Report.  

### Branch 3 – Government Registry
- **Source**: Danish Central Business Register (CVR.dk / Virk.dk extract: `novo_nordisk_virk.pdf`).  
- **Claim**: Official legal registry of Novo Nordisk A/S directors; matches names in Annual Report.  

---

## 🌳 Leaves (Axioms)
1. EU law (Directive (EU) 2022/2381) defines the gender balance thresholds.  
2. Novo Nordisk Annual Report 2024 is a legally binding governance disclosure.  
3. CVR (Virk.dk) is the authoritative Danish government record of directors.  
4. MarketScreener is an independent financial data provider.  
5. Ratio calculation: 6 ÷ 12 = 50% women.  

---

## ✅ Compliance Argument
- Requirement: ≥33% of all directors (or ≥40% of non-executives) must be the underrepresented sex.  
- Fact: Novo Nordisk has **50% women on its Board** in 2024.  
- Proof: Verified by company disclosure, independent financial database, and government registry.  
- **Conclusion**: Novo Nordisk is in **full compliance** with Directive (EU) 2022/2381.  
